Lowest Price Guaranteed From USD 4,799
Published
February 2021
Pages
296
View Count
11153
Example Insights
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Report Description
The cold chain logistics market for vaccines is estimated to be worth $4 billion globally. Over 95% of all approved biologics and 90% of all vaccines are cold chain dependent. According to the data presented by the WHO, the current global vaccination coverage is nearly 85%; however, it has been reported that 25% of vaccines are damaged due to cold chain malfunction (improper distribution and shipping). In some countries, about 80% of the drugs are estimated to lose their potency due to inadequate temperature control during their cold chain transportation. For some vaccines, even the slightest variations in temperature / storage conditions can adversely alter product integrity and / or viability. In this context, it is worth mentioning that there are several vaccines being developed against COVID-19; given the nature of the pathogen, these aforementioned product candidates are likely to be cold chain dependent. For example, the synthetic mRNA-based COVID vaccine being developed by Pfizer (which is, so far, the most promising candidate) is required to be stored at -70°C (-94°F) or lower. This fundamentally complicates the use and cold chain distribution for vaccines in temperate / equatorial regions, where distances between populated regions are vast and a proper cold chain infrastructure is lacking. Other healthcare products that need to be shipped / stored under low temperatures include aerosols, blood plasma, and certain diagnostics kits.
Considering the projected growth of the global population, it is likely that the demand for vaccines will indubitably increase. Consequently, well-defined cold chain infrastructure and established vaccine supply networks are crucial to the success of global level immunization initiatives. This is also true for all vaccination programs for COVID-19, which is an immediate and exigent concern. In other words, the biggest challenge in cold chain logistics is lack of / inadequate infrastructure to support the cold chain storage and / or transportation of vaccines. Moreover, connected cold chain solutions have been observed to offer a variety of advantages over conventional methodologies, such as automation of most of the steps and elimination of human handling errors that are associated with human intervention.
Over time, there has been significant consolidation in this industry, with stakeholders expanding their respective facilities / capabilities, and also making strategic acquisitions to better serve their growing clientele. Further, the logistics service providers are focused on devising and implementing flexible business strategies and technical advancements in order to cope with increased inflow of patients. The countries are also preparing for sustainable cold chain storage and distribution / supply of COVID-19 vaccine to different parts of globe, as the reliance on cold chain facilities for coronavirus vaccine is expected to increase substantially.
The ‘Cold Chain Logistics Market for Vaccines by Type of Vaccines (COVID-19 and Others), Type of Services (Storage, Packaging, and Transportation), Mode of Transportation (Ground, Air, and Ocean), Holding Temperature (Refrigerated, Frozen, and Deep Frozen / Cryogenic), Scale of Operation (Clinical and Commercial), Type of Container (Active and Passive), Type of Packaging Methods (Dry Ice, Liquid Nitrogen, and Gel Packs), End-Users (Industry and Non-Industry), Key Geographical Regions (North America, Europe, Asia, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2021-2030, report features an extensive study of the current landscape, offering an informed opinion on the likely evolution of this industry, by 2030. Further, the study underlines an in-depth analysis of players engaged in offering cold chain logistics services for vaccines. Amongst other elements, the report features:
One of the key objectives of the report was to estimate the existing market size and future growth potential within the cold chain logistics market for vaccines over the next decade. We have developed an informed estimate of the financial evolution of the market, over the period 2021-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] type of vaccines (COVID-19 and other vaccines), [B] holding temperature range (refrigerated, frozen, and cryogenic), [C] scale of operation (clinical and commercial), [D] type of container (active and passive containers), [E] end-user (industry and non-industry), and [F] key geographical regions (North America, Europe, Asia, Latin America (LATM), Middle East and North Africa (MENA) and Rest of the World). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the industry’s evolution.
The opinions and insights presented in this study were also influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order):
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of cold chain logistics market for vaccines in the short-mid term and long term.
Chapter 3 is an introductory chapter that provides a detailed comparison of the traditional supply chain and cold chain, along with information on the various processes and procedures associated with cold chain logistics, including a discussion on its historical evolution. It also elaborates on the key steps involved in cold chain logistic operations of temperature-sensitive vaccines, including cold chain storage, packaging, transportation and monitoring. Further, the chapter provides a brief overview of vaccines which require cold chain operations, along with inputs on their preferred storage / transportation temperature ranges. It also features a discussion on the various modes of transportation used for such shipments. Further, the chapter includes a discussion on the various advantages and limitations associated with cold chain logistics and management industry.
Chapter 4 features a detailed discussion on various complexities associated with the cold chain logistics operations for vaccines (including COVID-19 vaccine). It also highlights the criticality of cold chain logistics during product manufacturing, storage, packaging and transportation. Furthermore, it provides information on recommended cold chain temperature profiles and best practices for shipping and storage of such vaccines. The chapter also elaborates on the various challenges related to cold chain for vaccines and their solutions. It further includes an informative multi-valent analysis to highlight the logistical complexities related to vaccines based on several parameters, such as temperature conditions, delivery time restrictions, handling / transportation requirements, and storage related needs.
Chapter 5 includes information on close to 80 industry players offering cold chain logistics services for vaccines based on a number of relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, type of service(s) offered (storage, packaging, and transportation), mode of transportation used (ground, air, and ocean), holding temperature range (ambient, refrigerated, frozen, and deep frozen / cryogenic), type of packaging method adopted (dry ice, liquid nitrogen, and gel packs), type of container used (active and passive containers), end-user (healthcare and non-healthcare), availability of capabilities for transport of COVID-19 vaccine, location of cold chain facilities.
Chapter 6 features a contemporary market trend analysis, which includes [A] a tree map representation, comparing industry players on the basis of holding temperature range and company size, [B] a tree map representation, comparing industry players on the basis of holding temperature range and geographical activity, [C] a heat map representation comparing players on the basis of location of cold chain facility and geographical activity, [D] a grid representation which highlights the distribution of players based on mode of transportation, type of container and geographical activity, [E] a world map representation presenting the regional distribution of players engaged in this domain based on the location of their respective headquarters, and [F] a comparative grid representation to highlight the historical and current market landscape based on holding temperature range, mode of transportation, and geographical activity.
Chapter 7 features an insightful company competitiveness analysis, highlighting prominent logistics service providers, taking into consideration their supplier strength (in terms of experience of the service provider), and capabilities related to cold chain logistics (such as type of container, type of service(s) offered, holding temperature range, mode of transportation and location of cold chain facility).
Chapter 8 features elaborate profiles of prominent service providers (shortlisted on the basis of the company competitiveness analysis) engaged in this domain. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key members of the executive team), details related to their respective portfolios for cold chain services, recent developments, and an informed future outlook.
Chapter 9 elaborate discussion on the various regulatory guidelines that have been laid down by major regulatory bodies (such as European Medicines Agency (EMA), United States Food and Drug Administration (USFDA), Health Canada (HC), International Air Transport Association (IATA), International Safe Transit Association (ISTA), United States Pharmacopeia (USP), and World Health Organization (WHO)), specific to cold chain management. In addition, it features an insightful analysis, comparing these regulatory authorities based on the guidelines issued by them for different stages of the cold chain.
Chapter 10 provides detailed analysis of the recent developments and initiative (partnerships, expansions, and other strategic initiatives) that have been undertaken in the cold chain logistics market for vaccines, during the period between 2016 and 2021. The chapter also includes details on the initiatives taken by big-pharma players in the last few years.
Chapter 11 features detailed estimation of the likely demand for logistics services for COVID-19 vaccines and other vaccines (including over 15 types of mandatory and optional vaccines), considering the contributions from both clinical and commercially available products for infants and adults, over the period 2021-2030.
Chapter 12 highlights the recent COVID-19 pandemic is likely to impact the cold chain logistics market for vaccines, along with information on the key initiatives undertaken by service providers to overcome the challenges faced due to the pandemic.
Chapter 13 presents an insightful market forecast analysis, highlighting the future potential of cold chain logistics market till 2030. We have segmented the market on the basis of [A] type of vaccines (COVID-19 and other vaccines), [B] holding temperature range (refrigerated, frozen, and cryogenic), [C] scale of operation (clinical and commercial), [D] type of container (active and passive containers), [E] end-user (industry and non-industry), and [F] key geographical regions (North America, Europe, Asia, Latin America (LATM), Middle East and North Africa (MENA) and Rest of the World).
Chapter 14 features a detailed discussion on the upcoming tools / technologies (such as integration of automation and robotics, cloud computing, blockchain technology, artificial intelligence and other such advanced technical solutions) in the field of cold chain logistics and their likely impact on the future evolution of this market.
Chapter 15 summarizes the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the cold chain logistics market for vaccines.
Chapter 16 is a collection of transcripts of interviews conducted with various stakeholders in the industry. The chapter provides a brief overview of the companies and details of interviews held with Michael Vetter (Co-founder, Vetter Pharma), Sagar Brahme (Deputy General Manager, Lisaline Lifescience Technologies), Elena Boykova (Marketing Communications Manager, AirBridgeCargo Airlines), Michelle Arnot-Kruger (Health Specialist, Cold Chain Logistics, UNICEF), and Shehdeh Abusnineh (Supply Chain Manager, Tabuk Pharmaceuticals).
Chapter 17 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter 18 is an appendix, which contains the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Concept of Cold Chain Logistics
3.2.1. Comparison of Conventional Supply Chain and Cold Chain
3.2.2. Historical Evolution of the Cold Chain Logistics Industry
3.3. Cold Chain Logistics in Healthcare
3.4. Types of Healthcare Products Requiring Cold Chain Logistics
3.5. Types of Containers Used in Cold Chain Logistics
3.5.1. Active Cold Chain Containers
3.5.2. Passive Cold Chain Containers
3.5.3. Insulated Cold Chain Containers
3.6. Modes of Transportation Used in Cold Chain Logistics
3.6.1. Road Transportation
3.6.2. Air Transportation
3.6.3. Ocean / Marine Transportation
3.6.4. Rail Transportation
3.6.5. Intermodal and Multimodal Transportation
3.6.6. Comparison of Modes of Transportation
3.7. Advantages and Limitations of Cold Chain Logistics in Healthcare
3.8. Concluding Remarks
4. COLD CHAIN LOGISTICS FOR VACCINES
4.1. Chapter Overview
4.2. Introduction to Vaccines
4.3. Classification of Vaccines
4.4. Overview of Vaccine Logistics
4.5. Cold Storage
4.6. Challenges Related to Transporting Vaccines
4.6.1. Heat Sensitivity
4.6.2. Cross-Border Shipment Concerns
4.6.3. Container Related Concerns
4.7. Concluding Remarks
5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Cold Chain Logistics Service Providers for Vaccines: List of Players
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Type of Cold Chain Logistics Service(s) Offered
5.2.5. Analysis by Mode of Transportation
5.2.6. Analysis by Holding Temperature Range
5.2.7. Analysis by Type of Container Used
5.2.8. Analysis by End-User
5.2.9. Analysis by Geographical Activity
5.2.10. Analysis by Location of Cold Chain Facility
5.2.11. Analysis by Capabilities for COVID-19 Vaccine Transport
6. KEY INSIGHTS
6.1. Chapter Overview
6.2. Analysis by Holding Temperature Range and Company Size (Tree Map Representation)
6.3. Analysis by Holding Temperature Range and Geographical Activity (Tree Map Representation)
6.4. Analysis by Location of Cold Chain Facility and Geographical Activity (Heat Map Representation)
6.5. Analysis by Mode of Transportation, Type of Container and Geographical Activity (Grid Representation)
6.6. Analysis by Location of Headquarters (World Map Representation)
6.7. Historical and Current Market Landscape Trend Analysis
6.7.1. Peer Group I: Cold Chain Logistics Services at Ambient Temperature
6.7.2. Peer Group II: Cold Chain Logistics Services at Refrigerated Temperature
6.7.3. Peer Group III: Cold Chain Logistics Services at Frozen Temperature
6.7.4. Peer Group IV: Cold Chain Logistics Services at Deep Frozen / Cryogenic Temperature
7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Key Assumptions and Parameters
7.3. Methodology
7.3.1. Company Competitiveness: Small Companies
7.3.2. Company Competitiveness: Mid-Sized Companies
7.3.3. Company Competitiveness: Large Companies
7.4. Company Competitiveness: Benchmarking the Capabilities of Leading Players
8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Cryoport
8.2.1. Company Snapshot
8.2.2. Service / Product Portfolio
8.2.3. Recent Developments and Future Outlook
8.3. DHL Express
8.3.1. Company Snapshot
8.3.2. Service / Product Portfolio
8.3.3. Recent Developments and Future Outlook
8.4. GAC
8.4.1. Company Snapshot
8.4.2. Service / Product Portfolio
8.4.3. Recent Developments and Future Outlook
8.5. Lynden International Logistics
8.5.1. Company Snapshot
8.5.2. Service / Product Portfolio
8.5.3. Recent Developments and Future Outlook
8.6. PAREXEL
8.6.1. Company Snapshot
8.6.2. Service / Product Portfolio
8.6.3. Recent Developments and Future Outlook
8.7. United Parcel Service
8.7.1. Company Snapshot
8.7.2. Service / Product Portfolio
8.7.3. Recent Developments and Future Outlook
8.8. Yusen Logistics
8.8.1. Company Snapshot
8.8.2. Service / Product Portfolio
8.8.3. Recent Developments and Future Outlook
9. REGULATORY RECOMMENDATIONS AND GUIDELINES
9.1. Chapter Overview
9.2. Regulatory Guidelines Issued by International Authorities
9.2.1. World Health Organization (WHO)
9.2.2. International Air Transport Association (IATA)
9.2.3. International Safe Transit Association (ISTA)
9.3. Regulatory Guidelines for Cold Chain Management in the US
9.3.1. United States Food and Drug Administration (USFDA)
9.3.2. United States Pharmacopeia (USP)
9.4. Regulatory Guidelines for Cold Chain Management in Canada
9.4.1. Health Canada
9.5. Regulatory Guidelines for Cold Chain Management in Europe
9.5.1. European Medicine Agency (EMA)
9.6. Recommendations for Different Steps of Cold Chain Logistics
9.7. Comparative Analysis of Regulatory Authorities
10. RECENT DEVELOPMENTS AND INITIATIVES
10.1. Chapter Overview
10.2. Cold Chain Logistics for Vaccines: Recent Partnerships and Collaborations
10.2.1. Analysis by Year of Partnership
10.2.2. Analysis by Type of Partnership
10.2.2.1. Analysis by Year of Partnership and Type of Partnership
10.2.2.2. Analysis by Type of Partnership and Company Size
10.2.3. Most Active Players: Analysis by Number of Partnerships
10.2.4. Analysis by Region
10.2.4.1. Intercontinental and Intracontinental Agreements
10.3. Cold Chain Logistics for Vaccines: Recent Expansions
10.3.1. Analysis by Year of Expansion
10.3.2. Analysis by Geography
10.3.2. Analysis by Leading Players
10.4. Cold Chain Logistics for Vaccines: Big Pharma Players
10.5. Cold Chain Logistics for Vaccines: Google News
10.6. Cold Chain Logistics for Vaccines: Other Key Initiatives
11. DEMAND ANALYSIS FOR VACCINES
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Global Clinical Demand for Vaccines (Clinical Trial Analysis)
11.3.1. Analysis by Trial Registration Year
11.3.2. Analysis by Holding Temperature Range
11.3.3. Analysis by Type of Vaccines
11.3.4. Analysis by Trial Phase
11.3.5. Analysis by Trial Status
11.3.6. Analysis by Number of Clinical Trials and Region
11.3.7. Analysis by Trial Status, Trial Phase and Region
11.3.8. Analysis by Type of Sponsor / Collaborator
11.3.9. Most Active Players: Analysis by Number of Clinical Trials
11.4. Global Clinical Demand for Vaccines (Analysis of Enrolled Patient Population)
11.4.1. Analysis by Demand for COVID-19 Vaccines (Number of Enrolled Patients)
11.4.2. Analysis by Demand for Other Vaccines (Number of Enrolled Patients)
11.4.3. Analysis by Enrolled Patient Population and Region
11.4.4. Analysis of Enrolled Patient Population by Trial Phase, Holding Temperature Range and Region
11.4.5. Analysis of Enrolled Patient Population by Trial Phase, Type of Vaccine and Region
11.5. Global Commercial Demand for Vaccines (Annual Number of Doses Required)
11.5.1. Analysis by Type of Vaccine
11.5.2. Analysis for Mandatory Vaccines by Number of Doses and Region
11.5.3. Analysis for Optional Vaccines by Number of Doses and Region
11.5.4. Analysis for COVID-19 Vaccines by Number of Doses and Region
11.6. Concluding Remarks
12. COLD CHAIN LOGISTICS FOR COVID-19 VACCINE
12.1. Chapter Overview
12.2. Impact of COVID-19 Outbreak on Cold Chain Logistics for Vaccines
12.3. Impact on Future Market Opportunities for Cold Chain Logistics Service Providers for Vaccines
12.4. Current Opinions and Key Initiatives of Key Players
12.4.1. Strategies for Implementation in the Short / Mid Term
12.4.2. Strategies for Implementation in the Long Term
13. MARKET FORECAST
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Global Cold Chain Logistics Market for Vaccines, 2021-2030
13.4. Global Cold Chain Logistics Market for Vaccines: Distribution by Type of Vaccine
13.4.1. Cold Chain Logistics Market for COVID-19 Vaccines
13.4.2. Cold Chain Logistics Market for Other Vaccines
13.5. Global Cold Chain Logistics Market for Vaccines: Distribution by Holding Temperature Range
13.5.1. Cold Chain Logistics Market for Vaccines Requiring Refrigerated Temperature, 2021-2030
13.5.2. Cold Chain Logistics Market for Vaccines Requiring Frozen Temperature, 2021-2030
13.5.3. Cold Chain Logistics Market for Vaccines Requiring Cryogenic Temperature, 2021-2030
13.6. Global Cold Chain Logistics Market for Vaccines: Distribution by Scale of Operation
13.6.1. Cold Chain Logistics Market for Clinical Vaccines, 2021-2030
13.6.2. Cold Chain Logistics Market for Commercial Vaccines, 2021-2030
13.7. Global Cold Chain Logistics Market for Vaccines: Distribution by Type of Container
13.7.1. Cold Chain Logistics Market for Vacinnes for Active Containers, 2021-2030
13.7.2. Cold Chain Logistics Market for Vaccines for Passive Containers, 2021-2030
13.8. Global Cold Chain Logistics Market for Vaccines: Distribution by Type of End-User
13.8.1. Cold Chain Logistics Market for Vaccines for Industry Players, 2021-2030
13.8.2. Cold Chain Logistics Market for Vaccines for Non-Industry Players, 2021-2030
13.9. Global Cold Chain Logistics Market for Vaccines: Distribution by Geography
13.9.1. Cold Chain Logistics Market for Vaccines in North America, 2021-2030
13.9.1.1. Cold Chain Logistics Market for Vaccines in the US, 2021-2030
13.9.1.2. Cold Chain Logistics Market for Vaccines in Canada, 2021-2030
13.9.1.3. Cold Chain Logistics Market for Vaccines in Mexico, 2021-2030
13.9.2. Cold Chain Logistics Market for Vaccines in Europe, 2021-2030
13.9.2.1. Cold Chain Logistics Market for Vaccines in the UK, 2021-2030
13.9.2.2. Cold Chain Logistics Market for Vaccines in Germany, 2021-2030
13.9.2.3. Cold Chain Logistics Market for Vaccines in France, 2021-2030
13.9.2.4. Cold Chain Logistics Market for Vaccines in Spain, 2021-2030
13.9.2.5. Cold Chain Logistics Market for Vaccines in Italy, 2021-2030
13.9.3. Cold Chain Logistics Market for Vaccines in Asia, 2021-2030
13.9.3. Cold Chain Logistics Market for Vaccines in China, 2021-2030
13.9.3.2. Cold Chain Logistics Market for Vaccines in Japan, 2021-2030
13.9.3.3. Cold Chain Logistics Market for Vaccines in India, 2021-2030
13.9.4. Cold Chain Logistics Market for Vaccines in Latin America, 2021-2030
13.9.4.1. Cold Chain Logistics Market for Vaccines in Brazil, 2021-2030
13.9.5. Cold Chain Logistics Market for Vaccines in Middle East and North Africa (MENA), 2021-2030
13.9.5.1. Cold Chain Logistics Market for Vaccines in Israel, 2021-2030
13.9.4.2. Cold Chain Logistics Market for Vaccines in Saudi Arabia, 2021-2030
13.9.6. Cold Chain Logistics Market for Vaccines in Rest of the World, 2021-2030
13.9.6.1. Cold Chain Logistics Market for Vaccines in Australia, 2021-2030
13.9.6.2. Cold Chain Logistics Market for Vaccines in New Zealand, 2021-2030
13.10. Concluding Remarks
14. UPCOMING TRENDS AND FUTURE GROWTH OPPORTUNITIES
14.1. Chapter Overview
14.2. Connected Cold Chain: Key Tools and Affiliated Technologies
14.2.1. Artificial Intelligence
14.2.2. Augmented Reality
14.2.3. Automation and Robotics
14.2.4. Big Data Analytics
14.2.5. Blockchain Technology
14.2.6. Cloud Computing
14.2.7. Internet of Things
14.2.8. Radio Frequency Identification (RFID) Tags
14.3. Connected Cold Chain: Future Growth Opportunities
14.4. Real-Time Monitoring: An Application of Connected Cold Chain Solutions
14.4.1. Methods for Integration of Real-Time Monitoring in Cold Chain Logistics
14.4.1.1. RFID Based Real-Time Monitoring
14.4.1.2. Blockchain and IoT Based Real-Time Monitoring
14.4.2. Growth Opportunities for Real-Time Monitoring in Connected Cold Chain
14.4.3. Cost Benefits of Real-Time Monitoring in Cold Chain Logistics
15. CONCLUSION
15.1. Chapter Overview
15.2 Key Takeaways
16. EXECUTIVE INSIGHTS
16.1. Chapter Overview
16.2. Vetter Pharma
16.2.1. Company Snapshot
16.2.2. Interview Transcript: Michael Vetter, Co-founder
16.3. Lisaline Lifescience Technologies
16.3.1. Company Snapshot
16.3.2. Interview Transcript: Sagar Brahme, Deputy General Manager
16.4. AirBridgeCargo Airlines
16.4.1. Company Snapshot
16.4.2. Interview Transcript: Elena Boykova, Marketing Communications Manager
16.5. UNICEF
16.5.1. Company Snapshot
16.5.2. Interview Transcript: Michelle Arnot-Kruger, Health Specialist, Cold Chain Logistics
16.6. Tabuk Pharmaceuticals
16.6.1. Company Snapshot
16.6.2. Interview Transcript: Shehdeh Abusnineh, Supply Chain Manager
17. APPENDIX 1: TABULATED DATA
18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Key Steps Involved in the Supply Chain
Figure 3.2 Differences between Conventional Supply Chain and Cold Chain
Figure 3.3 Key Historical Milestones in the Cold Chain Logistics Industry
Figure 3.4 Applications of Cold Chain Logistics
Figure 3.5 Key Components of Cold Chain Logistics Process
Figure 3.6 Types of Healthcare Products requiring Cold Chain Logistics
Figure 3.7 Recommended Holding Temperature Ranges for Various Healthcare Products
Figure 3.8 Types of Active Cold Chain Containers
Figure 3.9 Types of Materials / Methods used in Passive Cold Chain Containers
Figure 3.10 Types of Insulated Cold Chain Containers
Figure 3.11 Key Considerations for Management of Road Shipments
Figure 3.12 Key Considerations for Management of Road Shipments using Passive Cold Chain Containers
Figure 3.13 Types of Carriers for Air Transportation
Figure 3.14 Key Considerations for Management of Air Shipments
Figure 3.15 Advantages and Limitations of Cold Chain Logistics in Healthcare
Figure 4.1 Key Steps in Vaccine Transportation Process
Figure 4.2 Key Considerations for Storage of Vaccines
Figure 4.3 Heat Sensitivity of Different Types of Vaccines
Figure 4.4 Types of Containers for Transportation of Vaccines
Figure 5.1 Cold Chain Logistics Service Providers for Vaccines: Distribution by Year of Establishment
Figure 5.2 Cold Chain Logistics Service Providers for Vaccines: Distribution by Company Size
Figure 5.3 Cold Chain Logistics Service Providers for Vaccines: Distribution by Location of Headquarters
Figure 5.4 Cold Chain Logistics Service Providers for Vaccines: Distribution by Type of Service(s) Offered
Figure 5.5 Cold Chain Logistics Service Providers for Vaccines: Distribution by Mode of Transportation
Figure 5.6 Cold Chain Logistics Service Providers for Vaccines: Distribution by Holding Temperature Range
Figure 5.7 Cold Chain Logistics Service Providers for Vaccines: Distribution by Type of Container Used and Packaging Method
Figure 5.8 Cold Chain Logistics Service Providers for Vaccines: Distribution by End-User
Figure 5.9 Cold Chain Logistics Service Providers for Vaccines: Distribution by Geographical Activity
Figure 5.10 Cold Chain Logistics Service Providers for Vaccines: Distribution by Location of Cold Chain Facility
Figure 5.11 Cold Chain Logistics Service Providers: Distribution by Capabilities for COVID-19 Vaccine Transport
Figure 6.1 Tree Map Representation: Distribution by Holding Temperature Range and Company Size
Figure 6.2 Tree Map Representation: Distribution by Holding Temperature Range and Geographical Activity
Figure 6.3 Heat Map Representation: Distribution by Location of Cold Chain Facility and Geographical Activity
Figure 6.4 Grid Analysis: Distribution by Mode of Transportation, Type of Container and Geographical Activity
Figure 6.5 World Map Representation: Distribution by Location of Headquarters
Figure 6.6 Historical and Current Market Landscape Trend Analysis for Ambient Temperature: Distribution by Mode of Transportation and Geographical Activity
Figure 6.7 Historical and Current Market Landscape Trend Analysis for Refrigerated Temperature: Distribution by Mode of Transportation and Geographical Activity
Figure 6.8 Historical and Current Market Landscape Trend Analysis for Frozen Temperature: Distribution by Mode of Transportation and Geographical Activity
Figure 6.9 Historical and Current Market Landscape Trend Analysis for Deep Frozen / Cryogenic Temperature: Distribution by Mode of Transportation and Geographical Activity
Figure 7.1 Company Competitiveness Analysis: Dot-Plot Representation (Small-Sized Players)
Figure 7.2 Company Competitiveness Analysis: Dot-Plot Representation (Mid-Sized Players)
Figure 7.3 Company Competitiveness Analysis: Dot-Plot Representation (Large-Sized Players)
Figure 7.4 Leading Cold Chain Logistics Service Providers for Vaccines
Figure 9.1 Cold Chain Logistics in Vaccines: International and Regional Regulatory Authorities
Figure 9.2 WHO Guidelines for Cold Chain Logistics
Figure 9.3 IATA (CEIV Pharma) Guidelines for Cold Chain Logistics
Figure 9.4 ISTA Guidelines for Cold Chain Logistics
Figure 9.5 USFDA Guidelines for Cold Chain Logistics
Figure 9.6 USFDA Form483s Excerpts: Challenges and Solutions Related to Cold Chain Logistics
Figure 9.7 USP Guidelines for Cold Chain Logistics
Figure 9.8 EMA Guidelines for Cold Chain Logistics
Figure 9.9 Regulatory Requirements for Various Steps of Cold Chain Logistics
Figure 9.10 Comparative Analysis of Regulatory Authorities
Figure 10.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2010-2021
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Figure 10.4 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Figure 10.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 10.6 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 10.7 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 10.11 Most Active Players: Distribution by Number of Partnerships
Figure 10.12 Partnerships and Collaborations: Distribution by Region
Figure 10.13 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Figure 10.14 Recent Expansions: Cumulative Year-Wise Trend, 2016-2021
Figure 10.15 Recent Expansions: Distribution by Year of Expansions
Figure 10.16 Recent Expansions: Distribution by Geography
Figure 10.17 Most Active Players: Distribution by Number of Expansions
Figure 10.18 Google News: Emerging Focus Area
Figure 11.1 Global Clinical Trials Demand for Vaccines: Cumulative Distribution by Registration Year
Figure 11.2 Global Clinical Trials Demand for Vaccines: Distribution by Holding Temperature Range
Figure 11.3 Global Clinical Demand for Vaccines: Distribution by Type of Vaccine
Figure 11.4 Global Clinical Demand for Vaccines: Distribution by Trial Phase
Figure 11.5 Global Clinical Trials Demand for Vaccines: Distribution by Trial Status
Figure 11.6 Global Clinical Trials Demand for Vaccines: Distribution by Number of Trials and Region
Figure 11.7 Global Clinical Trials Demand for Vaccines: Distribution by Trial Status, Trial Phase and Region
Figure 11.8 Global Clinical Trials Demand for Vaccines: Distribution by Type of Sponsor / Collaborator
Figure 11.9 Global Clinical Demand for Vaccines: Most Active Industry Players in Terms of Number of Trials Conducted
Figure 11.10 Most Active Industry Players: Distribution by Number of Trials
Figure 11.11 Most Active Non-Industry Players: Distribution by Number of Trials
Figure 11.12 Global Clinical Trials Demand for Vaccines: Distribution by Enrolled Patient Population
Figure 11.13 Global Clinical Demand for COVID-19 Vaccines: Distribution by Enrolled Patient Population
Figure 11.14 Global Clinical Demand for Other Vaccines: Distribution by Enrolled Patient Population
Figure 11.15 Global Clinical Demand for Vaccines: Distribution by Enrolled Patient Population and Region
Figure 11.16 Global Clinical Demand for Vaccines: Distribution of Enrolled Patient Population by Trial Phase, Holding Temperature Range and Region
Figure 11.17 Global Clinical Demand for Vaccines: Distribution of Enrolled Patient Population by Trial Phase, Type of Vaccine and Region
Figure 11.18 Global Commercial Demand for Vaccines: Distribution by Annual Number of Doses Required
Figure 11.19 Global Commercial Demand for Vaccines: Distribution by Type of Vaccine
Figure 11.20 Global Commercial Demand for Mandatory Vaccines: Distribution by Number of Doses and Region
Figure 11.21 Global Commercial Demand for Optional Vaccines: Distribution by Number of Doses and Region
Figure 11.22 Global Commercial Demand for COVID-19 Vaccines: Distribution by Number of Doses and Region
Figure 11.23 Global Commercial Demand for Vaccines: Distribution by Number of Doses (2021, 2025 and 2030)
Figure 12.1 Cold Chain Logistics Market for Vaccines, 2021-2030: COVID-19 Impact Scenario (USD Billion)
Figure 12.2 Key Players in Cold Chain Logistics for Vaccines Domain to Distribute COVID-19 Vaccines
Figure 13.1 Global Cold Chain Logistics Market for Vaccines, 2021-2030 (USD Million)
Figure 13.2 Global Cold Chain Logistics Market for Vaccines: Distribution by Type of Vaccine, 2021 and 2030
Figure 13.3 Global Cold Chain Logistics Market for COVID-19 Vaccines, 2021-2030 (USD Million)
Figure 13.4 Global Cold Chain Logistics Market for Other Vaccines, 2021-2030 (USD Million)
Figure 13.5 Global Cold Chain Logistics Market for Vaccines: Distribution by Holding Temperature Range, 2021 and 2030
Figure 13.6 Cold Chain Logistics Market for Vaccines Requiring Refrigerated Temperature, 2021-2030 (USD Million)
Figure 13.7 Cold Chain Logistics Market for Vaccines Requiring Frozen Temperature, 2021-2030 (USD Million)
Figure 13.8 Cold Chain Logistics Market for Vaccines Requiring Cryogenic Temperature, 2021-2030 (USD Million)
Figure 13.9 Global Cold Chain Logistics Market for Vaccines: Distribution by Scale of Operation, 2021 and 2030
Figure 13.10 Cold Chain Logistics Market for Vaccines for Clinical Vaccines, 2021-2030 (USD Million)
Figure 13.11 Cold Chain Logistics Market for Vaccines for Commercial Vaccines, 2021-2030 (USD Million)
Figure 13.12 Global Cold Chain Logistics Market for Vaccines: Distribution by Type of Container, 2021 and 2030
Figure 13.13 Cold Chain Logistics Market for Vacinnes for Active Containers, 2021-2030 (USD Million)
Figure 13.14 Cold Chain Logistics Market for Vaccines for Passive Containers, 2021-2030 (USD Million)
Figure 13.15 Global Cold Chain Logistics Market for Vaccines: Distribution by Type of End-User, 2021 and 2030
Figure 13.16 Cold Chain Logistics Market for Vaccines of Industry Players, 2021-2030 (USD Million)
Figure 13.17 Cold Chain Logistics Market for Vaccines of Non-Industry Players, 2021-2030 (USD Million)
Figure 13.18 Global Cold Chain Logistics Market for Vaccines: Distribution by Geography, 2021 and 2030
Figure 13.19 Cold Chain Logistics Market for Vaccines in North America, 2021-2030 (USD Million)
Figure 13.20 Cold Chain Logistics Market for Vaccines in the US, 2021-2030 (USD Million)
Figure 13.21 Cold Chain Logistics Market for Vaccines in Canada, 2021-2030 (USD Million)
Figure 13.22 Cold Chain Logistics Market for Vaccines in Mexico, 2021-2030 (USD Million)
Figure 13.23 Cold Chain Logistics Market for Vaccines in Europe, 2021-2030 (USD Million)
Figure 13.24 Cold Chain Logistics Market for Vaccines in the UK, 2021-2030 (USD Million)
Figure 13.25 Cold Chain Logistics Market for Vaccines in Germany, 2021-2030 (USD Million)
Figure 13.26 Cold Chain Logistics Market for Vaccines in France, 2021-2030 (USD Million)
Figure 13.27 Cold Chain Logistics Market for Vaccines in Spain, 2021-2030 (USD Million)
Figure 13.28 Cold Chain Logistics Market for Vaccines in Italy, 2021-2030 (USD Million)
Figure 13.29 Cold Chain Logistics Market for Vaccines in Asia, 2021-2030 (USD Million)
Figure 13.30 Cold Chain Logistics Market for Vaccines in China, 2021-2030 (USD Million)
Figure 13.31 Cold Chain Logistics Market for Vaccines in Japan, 2021-2030 (USD Million)
Figure 13.32 Cold Chain Logistics Market for Vaccines in India, 2021-2030 (USD Million)
Figure 13.33 Cold Chain Logistics Market for Vaccines in Latin America, 2021-2030 (USD Million)
Figure 13.34 Cold Chain Logistics Market for Vaccines in Brazil, 2021-2030 (USD Million)
Figure 13.35 Cold Chain Logistics Market for Vaccines in Middle East and North Africa (MENA), 2021-2030 (USD Million)
Figure 13.36 Cold Chain Logistics Market for Vaccines in Israel , 2021-2030 (USD Million)
Figure 13.37 Cold Chain Logistics Market for Vaccines in Saudi Arabia, 2021-2030 (USD Million)
Figure 13.38 Cold Chain Logistics Market for Vaccines in Rest of the World, 2021-2030 (USD Million)
Figure 13.39 Cold Chain Logistics Market for Vaccines in Australia, 2021-2030 (USD Million)
Figure 13.40 Cold Chain Logistics Market for Vaccines in New Zealand, 2021-2030 (USD Million)
Figure 13.41 Cold Chain Logistics Market for Vaccines: Conservative, Base and Optimistic Scenarios, 2021, 2025 and 2030 (USD Million)
Figure 14.1 Connected Cold Chain Solutions: Process Flow Diagram
Figure 14.2 Artificial Intelligence in Cold Chain Logistics: Key Benefits and Challenges
Figure 14.3 Augmented Reality in Cold Chain Logistics: Key Benefits and Challenges
Figure 14.4 Automation and Robotics in Cold Chain Logistics: Key Benefits and Challenges
Figure 14.5 Big Data Analytics in Cold Chain Logistics: Key Benefits and Challenges
Figure 14.6 Blockchain Technology in Cold Chain Logistics: Key Benefits and Challenges
Figure 14.7 Cloud Computing in Cold Chain Logistics: Key Benefits and Challenges
Figure 14.8 Internet of Things in Cold Chain Logistics: Schematic Representation
Figure 14.9 Internet of Things in Cold Chain Logistics: Key Benefits and Challenges
Figure 14.10 RFID in Cold Chain Logistics: Key Benefits and Challenges
Figure 14.11 Connected Cold Chain: Harvey Ball Analysis of Future Growth Opportunities
Figure 14.12 Real-Time Monitoring: Conventional Devices
Figure 14.13 RFID Based Real-Time Monitoring in Cold Chain Logistics
Figure 14.14 Key Contributions of Blockchain Technology and IoT in Real-Time Monitoring
Figure 14.15 Blockchain Technology and IoT Based Real-Time Monitoring: Flow Diagram
Figure 14.16 Real-Time Monitoring in Cold Chain Management: Growth Opportunities
Figure 14.17 Real-Time Monitoring: Reduction in Cost of Cold Chain Logistics
Figure 15.1 Concluding Remarks: Current Market Landscape
Figure 15.2 Concluding Remarks: Recent Developments and Initiatives
Figure 15.3 Concluding Remarks: Global Demand for Vaccines
Figure 15.4 Concluding Remarks: Market Sizing and Opportunity Analysis
Table 3.1 Comparison of Different Modes of Transportation
Table 4.1 Classification of Vaccines Based on Method of Development
Table 4.2 Recommended Holding Temperature Ranges for Different Type of Vaccines
Table 4.3 Logistics Complexity Analysis for Vaccines
Table 5.1 Cold Chain Logistics Service Providers for Vaccines: Information on Industry Players
Table 5.2 Cold Chain Logistics Service Providers for Vaccines: Information on Services Offered
Table 5.3 Cold Chain Logistics Service Providers for Vaccines: Information on Mode of Transportation
Table 5.4 Cold Chain Logistics Service Providers for Vaccines: Information on Holding Temperature Range
Table 5.5 Cold Chain Logistics Service Providers for Vaccines: Information on Type of Container Used and Packaging Method
Table 5.6 Cold Chain Logistics Service Providers for Vaccines: Information on End-Users
Table 5.7 Cold Chain Logistics Service Providers for Vaccines: Details on Geographical Activity (Continent-wise)
Table 5.8 Cold Chain Logistics Service Providers for Vaccines: Details on Location of Cold Chain Facility North America, Europe and Asia (Country-wise)
Table 5.9 Cold Chain Logistics Service Providers for Vaccines: Details on Location of Cold Chain Facility in Latin America, MENA and RoW (Country-wise)
Table 7.1 Company Competitiveness Analysis: Small Companies
Table 7.2 Company Competitiveness Analysis: Mid-Sized Companies
Table 7.3 Company Competitiveness Analysis: Large Companies
Table 8.1 Cold Chain Logistics Service Providers for Vaccines: List of Companies Profiled
Table 8.2 Cryoport: Company Snapshot
Table 8.3 Cryoport: Recent Developments and Future Outlook
Table 8.4 DHL Express: Company Snapshot
Table 8.5 DHL Express: Recent Developments and Future Outlook
Table 8.6 GAC: Company Snapshot
Table 8.7 GAC: Recent Developments and Future Outlook
Table 8.8 Lynden International Logistics: Company Snapshot
Table 8.9 Lynden International Logistics: Recent Developments and Future Outlook
Table 8.10 PAREXEL: Company Snapshot
Table 8.11 PAREXEL: Recent Developments and Future Outlook
Table 8.12 United Parcel Service: Company Snapshot
Table 8.13 United Parcel Service: Recent Developments and Future Outlook
Table 8.14 Yusen Logistics: Company Snapshot
Table 8.15 Yusen Logistics: Recent Developments and Future Outlook
Table 10.1 Partnerships and Collaborations: Information on Year of Agreement, Type of Partnership Model and Partner, 2015-2021
Table 10.2 Partnerships and Collaborations: Information on Type of Agreement and Type of Service(s) Offered, 2015-2021
Table 10.3 Recent Expansions: List of Expansions, 2016-2021
Table 10.4 Cold Chain Logistics for Vaccines: Recent Initiatives of Big Pharma Players
Table 10.5 Cold Chain Logistics for Vaccines: Other Recent Key Initiatives
Table 12.1 Cold Chain Logistics for Vaccines: Collaborations Focused on COVID-19
Table 14.1 Artificial Intelligence in Cold Chain Logistics: List of Companies
Table 14.2 Automation and Robotics in Cold Chain Logistics: List of Companies
Table 14.3 Big Data Analytics in Cold Chain Logistics: List of Companies
Table 14.4 Blockchain Technology in Cold Chain Logistics: List of Companies
Table 14.5 Cloud Computing in Cold Chain Logistics: List of Companies
Table 14.6 Internet of Things in Cold Chain Logistics: List of Companies
Table 14.7 RFID Tags in Cold Chain Logistics: List of Companies
Table 16.1 Vetter Pharma: Company Snapshot
Table 16.2 Lisaline Lifescience Technologies: Company Snapshot
Table 16.3 AirBridgeCargo Airlines: Company Snapshot
Table 16.4 UNICEF: Company Snapshot
Table 16.5 Tabuk Pharmaceuticals: Company Snapshot
Table 17.1 Cold Chain Logistics Service Providers for Vaccines: Distribution by Year of Establishment
Table 17.2 Cold Chain Logistics Service Providers for Vaccines: Distribution by Company Size
Table 17.3 Cold Chain Logistics Service Providers for Vaccines: Distribution by Location of Headquarters
Table 17.4 Cold Chain Logistics Service Providers for Vaccines: Distribution by Type of Service(s) Offered
Table 17.5 Cold Chain Logistics Service Providers for Vaccines: Distribution by Mode of Transportation
Table 17.6 Cold Chain Logistics Service Providers for Vaccines: Distribution by Holding Temperature Range
Table 17.7 Cold Chain Logistics Service Providers for Vaccines: Distribution by Type of Packaging Method
Table 17.8 Cold Chain Logistics Service Providers for Vaccines: Distribution by Type of Container Used
Table 17.9 Cold Chain Logistics Service Providers for Vaccines: Distribution by End-User
Table 17.10 Cold Chain Logistics Service Providers for Vaccines: Distribution by Geographical Activity
Table 17.11 Cold Chain Logistics Service Providers for Vaccines: Distribution by Location of Cold Chain Facility
Table 17.12 Cold Chain Logistics Service Providers: Distribution by Capabilities for COVID-19 Vaccine Transport
Table 17.13 Tree Map Representation: Distribution by Holding Temperature Range and Company Size
Table 17.14 Tree Map Representation: Distribution by Holding Temperature Range and Geographical Activity
Table 17.15 Heat Map Representation: Distribution by Location of Cold Chain Facility and Geographical Activity
Table 17.16 Grid Analysis: Distribution by Mode of Transportation, Type of Container and Geographical Activity
Table 17.17 World Map Representation: Distribution by Location of Headquarters
Table 17.18 Historical and Current Market Landscape Trend Analysis for Ambient Temperature: Distribution by Mode of Transportation and Geographical Activity
Table 17.19 Historical and Current Market Landscape Trend Analysis for Refrigerated Temperature: Distribution by Mode of Transportation and Geographical Activity
Table 17.20 Historical and Current Market Landscape Trend Analysis for Frozen Temperature: Distribution by Mode of Transportation and Geographical Activity
Table 17.21 Historical and Current Market Landscape Trend Analysis for Deep Frozen / Cryogenic Temperature: Distribution by Mode of Transportation and Geographical Activity
Table 17.22 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2010-2021
Table 17.23 Partnerships and Collaborations: Distribution by Type of Partnership
Table 17.24 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Table 17.25 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Table 17.26 Partnerships and Collaborations: Distribution by Type of Partner
Table 17.27 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 17.28 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 17.29 Most Active Players: Distribution by Number of Partnerships
Table 17.30 Partnerships and Collaborations: Distribution by Region
Table 17.31 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Table 17.32 Recent Expansions: Cumulative Year-Wise Trend, 2016-2021
Table 17.33 Recent Expansions: Distribution by Year of Expansions
Table 17.34 Recent Expansions: Distribution by Geography
Table 17.35 Most Active Players: Distribution by Number of Expansions
Table 17.36 Global Clinical Trials Demand for Vaccines: Cumulative Distribution by Registration Year
Table 17.37 Global Clinical Trials Demand for Vaccines: Distribution by Holding Temperature Range
Table 17.37 Global Clinical Demand for Vaccines: Distribution by Type of Vaccine
Table 17.38 Global Clinical Demand for Vaccines: Distribution by Trial Phase
Table 17.39 Global Clinical Trials Demand for Vaccines: Distribution by Trial Status
Table 17.40 Global Clinical Trials Demand for Vaccines: Distribution by Number of Trials and Region
Table 17.41 Global Clinical Trials Demand for Vaccines: Distribution by Trial Status, Trial Phase and Region
Table 17.42 Global Clinical Trials Demand for Vaccines: Distribution by Type of Sponsor / Collaborator
Table 17.43 Global Clinical Demand for Vaccines: Most Active Industry Players in Terms of Number of Trials Conducted
Table 17.44 Most Active Industry Players: Distribution by Number of Trials
Table 17.45 Most Active Non-Industry Players: Distribution by Number of Trials
Table 17.46 Global Clinical Trials Demand for Vaccines: Distribution by Enrolled Patient Population
Table 17.47 Global Clinical Demand for COVID-19 Vaccines: Distribution by Enrolled Patient Population
Table 17.48 Global Clinical Demand for Other Vaccines: Distribution by Enrolled Patient Population
Table 17.49 Global Clinical Demand for Vaccines: Distribution by Enrolled Patient Population and Region
Table 17.50 Global Clinical Demand for Vaccines: Distribution of Enrolled Patient Population by Trial Phase, Holding Temperature Range and Region
Table 17.51 Global Clinical Demand for Vaccines: Distribution of Enrolled Patient Population by Trial Phase, Type of Vaccine and Region
Table 17.52 Global Commercial Demand for Vaccines: Distribution by Annual Number of Doses Required
Table 17.53 Global Commercial Demand for Vaccines: Distribution by Type of Vaccine
Table 17.54 Global Commercial Demand for Mandatory Vaccines: Distribution by Number of Doses and Region
Table 17.55 Global Commercial Demand for Optional Vaccines: Distribution by Number of Doses and Region
Table 17.56 Global Commercial Demand for COVID-19 Vaccines: Distribution by Number of Doses and Region
Table 17.57 Global Commercial Demand for Vaccines: Distribution by Number of Doses (2021, 2025 and 2030)
Table 17.58 Cold Chain Logistics Market for Vaccines, 2021-2030: COVID-19 Impact Scenario (USD Billion)
Table 17.59 Global Cold Chain Logistics Market for Vaccines, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.60 Global Cold Chain Logistics Market for Vaccines: Distribution by Type of Vaccine, 2021 and 2030
Table 17.61 Global Cold Chain Logistics Market for COVID-19 Vaccines, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.62 Global Cold Chain Logistics Market for Other Vaccines, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.63 Global Cold Chain Logistics Market for Vaccines: Distribution by Holding Temperature Range, 2021 and 2030
Table 17.64 Cold Chain Logistics Market for Vaccines Requiring Refrigerated Temperature, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.65 Cold Chain Logistics Market for Vaccines Requiring Frozen Temperature, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.66 Cold Chain Logistics Market for Vaccines Requiring Cryogenic Temperature, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.67 Global Cold Chain Logistics Market for Vaccines: Distribution by Scale of Operation, 2021 and 2030
Table 17.68 Cold Chain Logistics Market for Clinical Vaccines, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.69 Cold Chain Logistics Market for Commercial Vaccines, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.70 Global Cold Chain Logistics Market for Vaccines: Distribution by Type of Container, 2021 and 2030
Table 17.71 Cold Chain Logistics Market for Vacinnes for Active Containers, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.72 Cold Chain Logistics Market for Vaccines for Passive Containers, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.73 Global Cold Chain Logistics Market for Vaccines: Distribution by Type of End-User, 2021 and 2030
Table 17.74 Cold Chain Logistics Market for Vaccines of Industry Players, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.75 Cold Chain Logistics Market for Vaccines of Non-Industry Players, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.76 Global Cold Chain Logistics Market for Vaccines: Distribution by Geography, 2021 and 2030
Table 17.77 Cold Chain Logistics Market for Vaccines in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.78 Cold Chain Logistics Market for Vaccines in the US, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.79 Cold Chain Logistics Market for Vaccines in Canada, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.80 Cold Chain Logistics Market for Vaccines in Mexico, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.81 Cold Chain Logistics Market for Vaccines in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.82 Cold Chain Logistics Market for Vaccines in the UK, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.83 Cold Chain Logistics Market for Vaccines in Germany, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.84 Cold Chain Logistics Market for Vaccines in France, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.85 Cold Chain Logistics Market for Vaccines in Spain, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.86 Cold Chain Logistics Market for Vaccines in Italy, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.87 Cold Chain Logistics Market for Vaccines in Asia, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.88 Cold Chain Logistics Market for Vaccines in China, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.89 Cold Chain Logistics Market for Vaccines in Japan, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.90 Cold Chain Logistics Market for Vaccines in India, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.91 Cold Chain Logistics Market for Vaccines in Latin America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.92 Cold Chain Logistics Market for Vaccines in Brazil, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.93 Cold Chain Logistics Market for Vaccines in Middle East and North Africa (MENA), Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.94 Cold Chain Logistics Market for Vaccines in Israel, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.95 Cold Chain Logistics Market for Vaccines in Saudi Arabia, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.96 Cold Chain Logistics Market for Vaccines in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.97 Cold Chain Logistics Market for Vaccines in Australia, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 17.98 Cold Chain Logistics Market for Vaccines in New Zealand, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
The following companies / institutes / government bodies and organizations have been mentioned in this report.
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
YOU MAY ALSO LIKE
SUBSCRIBE TO INDUSTRY UPDATES